PharmacoEconomics

, Volume 32, Issue 8, pp 745–758

Economic Evaluations of Gastroesophageal Reflux Disease Medical Management

  • Andrew J. Gawron
  • Dustin D. French
  • John E. Pandolfino
  • Colin W. Howden
Systematic Review

DOI: 10.1007/s40273-014-0164-8

Cite this article as:
Gawron, A.J., French, D.D., Pandolfino, J.E. et al. PharmacoEconomics (2014) 32: 745. doi:10.1007/s40273-014-0164-8

Abstract

Background

Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments.

Objectives

Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations.

Methods

We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis.

Results

Eighteen articles were included in the final analysis; 61 % of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence (>40 %). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3–10 years. Endoscopic anti-reflux procedures were not cost effective based on available data.

Conclusions

Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Andrew J. Gawron
    • 1
    • 2
  • Dustin D. French
    • 2
    • 3
  • John E. Pandolfino
    • 1
  • Colin W. Howden
    • 1
  1. 1.Division of Gastroenterology and HepatologyFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  2. 2.Center for Healthcare StudiesFeinberg School of Medicine, Northwestern UniversityChicagoUSA
  3. 3.Department of OphthalmologyFeinberg School of Medicine, Northwestern UniversityChicagoUSA

Personalised recommendations